High Note Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.6K Sell
17
-4
-19% -$2.72K ﹤0.01% 393
2026
Q1
$16.2K Buy
21
+2
+11% +$1.53K ﹤0.01% 303
2025
Q4
$14.7K Sell
19
-2
-10% -$1.36K ﹤0.01% 293
2025
Q3
$11.8K Sell
21
-9
-30% -$5.09K ﹤0.01% 297
2025
Q2
$15.8K Buy
30
+25
+500% +$14K ﹤0.01% 261
2025
Q1
$3.17K Sell
5
-7
-58% -$4.82K ﹤0.01% 579
2024
Q4
$8.55K Buy
+12
New +$10.1K ﹤0.01% 314

Other funds holding REGN

High Note Wealth's REGN Position: Q2 2026 in Review

High Note Wealth reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, selling an estimated $2.72K and leaving 17 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #393.

High Note Wealth first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.2K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • High Note Wealth held 17 shares of Regeneron Pharmaceuticals worth $10.6K as of Q2 2026.
  • High Note Wealth sold 4 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.72K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of High Note Wealth's portfolio in Q2 2026, its #393 holding.
  • High Note Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • High Note Wealth's Regeneron Pharmaceuticals position peaked at $16.2K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on High Note Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.